MedTrace Logo

EScitalopram PIndolol ONset of Action

NCT01219686 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-05-27

No results posted yet for this study

Summary

The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.

Conditions

  • Unipolar Depression

Interventions

DRUG

escitalopram, pindolol

escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17

DRUG

escitalopram

escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg

DRUG

escitalopram

escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg

Sponsors & Collaborators

  • University Hospital, Geneva

    collaborator OTHER

  • University of Lausanne Hospitals

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Markus KOSEL

    lead OTHER

Principal Investigators

  • Markus Kosel, MD-PhD · University Hospital, Geneva

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-04-30
Completion
2013-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219686 on ClinicalTrials.gov